ClinicalTrials.gg
Active, not recruitingNCT05921994ANIMAUpdated Nov 16, 2026

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.

An observational study in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 80 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
436
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Enrollment
Largest of 10
436 · median 125
Started
2023
the only one that year
Observational
10 of 21
6 open now
Primary completion
2027-03
later than 2 of 13 live
Registered
7th of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one has the largest enrollment of the 10 observational ones that give a count, is the only one that started in 2023, is one of 10 observational ones, reaches primary completion later than 2 of the 13 other live ones, and was the 7th registered.

Hidradenitis Suppurativa

286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.

Read the detailed description

The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.

In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis suppurativa
  • HS
  • secukinumab
  • Germany
  • NIS
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:

  1. Patients who provide written to participate in the study
  2. Male and female patients with ≥18 years of age
  3. Diagnosis of clinically unequivocal moderate to severe HS
  4. Patients for whom a therapy with secukinumab is medically indicated
  5. Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
  6. Treatment with secukinumab according to the latest version of SmPC
  7. Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit

Exclusion criteria

Exclusion Criteria:

Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:

  1. Patients who have any , such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
  2. Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
  3. Simultaneous participation in any trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
  4. Previous exposure to IL-17 inhibitors
  5. For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
436 participants (actual)
Patient registry
No

Groups and cohorts

  • secukinumab

    Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

    Other: secukinumab

Interventions

  • Othersecukinumab

    Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.

06

What researchers measure

Primary outcomes

  1. Proportion of patients receiving up-titration

    Proportion of patients receiving up-titration (q4w-to-q2w)

    Time frame: Up to 24 months

  2. Proportion of patients receiving down-titration

    Proportion of patients receiving down-titration (q2w-to-q4w)

    Time frame: Up to 24 months

  3. Time to up-titration and down-titration

    Time to up-titration and down-titration

    Time frame: Up to 2 years

  4. Duration of q4w treatment with secukinumab after dose reduction

    Duration of q4w treatment with secukinumab after dose reduction

    Time frame: Up to 2 years

  5. Proportion of patients who receive more than one up-and/or down titration

    Proportion of patients who receive more than one up-and/or down titration

    Time frame: Up to 24 months

  6. Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab

    Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab

    Time frame: Up to 2 years

  7. Number and type of surgical interventions

    Number and type of surgical interventions * minor and major surgical excision; * inpatient, outpatient

    Time frame: Up to 2 years

  8. Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)

    The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + \[number of draining tunnels (fistulae/sinuses) multiplied by 4\]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

    Time frame: Up to 24 months

  9. mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)

    The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + \[number of draining tunnels (fistulae/sinuses) multiplied by 4\]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

    Time frame: Up to 24 months

  10. Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire

    The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.

    Time frame: Up to 24 months

  11. Mean reduction of Abscesses and inflammatory nodules (AN) count

    Mean reduction of Abscesses and inflammatory nodules (AN) count

    Time frame: Up to 24 months

  12. Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)

    The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form.

    Time frame: Up to 24 months

07

Study locations

80 sites
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79068, Germany
  • Novartis Investigative Site
    Rheinstetten, Baden-Wurttemberg 76287, Germany
  • Novartis Investigative Site
    Haßfurt, Bavaria 97437, Germany
  • Novartis Investigative Site
    Kulmbach, Bavaria 95326, Germany
  • Novartis Investigative Site
    Lauf an der Pegnitz, Bavaria 91207, Germany
  • Novartis Investigative Site
    Nuremberg, Bavaria 90402, Germany
  • Novartis Investigative Site
    Panketal, Brandenburg 16341, Germany
  • Novartis Investigative Site
    Hamburg, Free and Hanseatic City of Hamburg 22549, Germany
  • Novartis Investigative Site
    Lingen, Lower Saxony 49809, Germany
  • Novartis Investigative Site
    Bergen auf Rügen, Mecklenburg-Vorpommern 18528, Germany
  • Novartis Investigative Site
    Kröpelin, Mecklenburg-Vorpommern 18236, Germany
  • Novartis Investigative Site
    Krefeld, North Rhine-Westphalia 47798, Germany
  • Novartis Investigative Site
    Mainz, Rhineland-Palatinate 55128, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04207, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04289, Germany
  • Novartis Investigative Site
    Wittenberg, Saxony-Anhalt 06886, Germany
  • Novartis Investigative Site
    Aachen, 52064, Germany
  • Novartis Investigative Site
    Ahaus, 48683, Germany
  • Novartis Investigative Site
    Annaberg-Buchholz, 09456, Germany
  • Novartis Investigative Site
    Bad Steben, 95138, Germany
  • Novartis Investigative Site
    Baden-Baden, 76530, Germany
  • Novartis Investigative Site
    Berlin, 12159, Germany
  • Novartis Investigative Site
    Berlin, 13595, Germany
  • Novartis Investigative Site
    Bielefeld, 33647, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    Brandenburg, 14776, Germany
  • Novartis Investigative Site
    Bremen, 28359, Germany
  • Novartis Investigative Site
    Buxtehude, 21614, Germany
  • Novartis Investigative Site
    Bückeburg, 31675, Germany
  • Novartis Investigative Site
    Chemnitz, 09113, Germany
  • Novartis Investigative Site
    Chemnitz, 09117, Germany
  • Novartis Investigative Site
    Cologne, 51065, Germany
  • Novartis Investigative Site
    Delitzsch, 04509, Germany
  • Novartis Investigative Site
    Dessau, 06847, Germany
  • Novartis Investigative Site
    Dorsten, 46282, Germany
  • Novartis Investigative Site
    Dortmund, 44137, Germany
  • Novartis Investigative Site
    Dresden, 01309, Germany
  • Novartis Investigative Site
    Düren, 52349, Germany
  • Novartis Investigative Site
    Emsdetten, 48282, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Falkenberg, 04895, Germany
  • Novartis Investigative Site
    Falkensee, 14612, Germany
  • Novartis Investigative Site
    Freising, 85354, Germany
  • Novartis Investigative Site
    Geilenkirchen, 52511, Germany
  • Novartis Investigative Site
    Gera, 07548, Germany
  • Novartis Investigative Site
    Gernsbach, 76593, Germany
  • Novartis Investigative Site
    Gladbeck, 45964, Germany
  • Novartis Investigative Site
    Großenhain, 01558, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hamburg, 22143, Germany
  • Novartis Investigative Site
    Hanover, 30159, Germany
  • Novartis Investigative Site
    Haslach im Kinzigtal, 77716, Germany
  • Novartis Investigative Site
    Hofgeismar, 34369, Germany
  • Novartis Investigative Site
    Jena, 07743, Germany
  • Novartis Investigative Site
    Jülich, 52428, Germany
  • Novartis Investigative Site
    Karlsruhe, 76133, Germany
  • Novartis Investigative Site
    Kempen, 47906, Germany
  • Novartis Investigative Site
    Lübeck, 23538, Germany
  • Novartis Investigative Site
    Magdeburg, 39104, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Mainz, 55116, Germany
  • Novartis Investigative Site
    Marburg, 35043, Germany
  • Novartis Investigative Site
    Minden, 32429, Germany
  • Novartis Investigative Site
    Mönchengladbach, 41063, Germany
  • Novartis Investigative Site
    Neu Wulmstorf, 21629, Germany
  • Novartis Investigative Site
    Nuremberg, 90419, Germany
  • Novartis Investigative Site
    Oberasbach, 90522, Germany
  • Novartis Investigative Site
    Oelde, 59302, Germany
  • Novartis Investigative Site
    Peitz, 03185, Germany
  • Novartis Investigative Site
    Potsdam, 14469, Germany
  • Novartis Investigative Site
    Remscheid, 42897, Germany
  • Novartis Investigative Site
    Selters, 56242, Germany
  • Novartis Investigative Site
    Simmern, 55469, Germany
  • Novartis Investigative Site
    Soest, 59494, Germany
  • Novartis Investigative Site
    Stolberg, 52222, Germany
  • Novartis Investigative Site
    Unna, 59423, Germany
  • Novartis Investigative Site
    Wittlich, 54316, Germany
  • Novartis Investigative Site
    Wuppertal, 42103, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Mar 2027, 43 months after the start.

Of 46 observational studies under Hidradenitis Suppurativa, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 25. This study's planned 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2023
First posted
Jun 28, 2023
StartActual
Aug 10, 2023
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05921994
Responsible party
Sponsor
First posted
Jun 28, 2023
Start date
Aug 10, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion